SCHEMBL856333

SCHEMBL856333

O=C1C=CC(=O)N1c1c[nH]c2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 1/20 0.52
MGLL Q99685 8/20 0.48
DNMT1 P26358 1/20 0.44
SIRT2 Q8IXJ6 2/20 0.44
SIRT1 Q96EB6 1/20 0.44
PRKD3 O94806 1/20 0.43
CCNB2 O95067 1/20 0.43
CCNE2 O96020 1/20 0.43
ABL1 P00519 1/20 0.43
PRKCG P05129 1/20 0.43
PRKCB P05771 1/20 0.43
CDK1 P06493 1/20 0.43
PIM1 P11309 1/20 0.43
CDK4 P11802 1/20 0.43
CCNB1 P14635 1/20 0.43
PRKCA P17252 1/20 0.43
PRKACA P17612 1/20 0.43
PRKACG P22612 1/20 0.43
PRKACB P22694 1/20 0.43
CCND1 P24385 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27519391 0.82 MGLL (0.51) TLR9MGLLSIRT2SIRT1PRKD3
SCHEMBL3044022 0.80 SMN1; SMN2 (0.43) SIRT2SIRT1PRKD3CCNB2CCNE2
SCHEMBL30688235 0.80 SMN1; SMN2 (0.43) SIRT2SIRT1PRKD3CCNB2CCNE2
SCHEMBL31727125 0.77 SMN1; SMN2 (0.48) SIRT2SIRT1PRKD3CCNB2CCNE2
SCHEMBL27910874 0.77 SIRT2 (0.41) SIRT2SIRT1PRKD3CCNB2CCNE2
SCHEMBL7198015 0.77 SIRT2 (0.44) TLR9MGLLSIRT2SIRT1PRKD3
SCHEMBL28340162 0.76 TLR9 (0.50) TLR9MGLLMAPTAHR
SCHEMBL10433673 0.76 F7 (0.49) TLR9MGLLCDK4CCND1GPR84
SCHEMBL10433671 0.76 NPSR1 (0.49) MGLLMEN1CYP3A4MAPTKMT2A
SCHEMBL10433692 0.76 HPGD (0.42) TLR9MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 486 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117276670-A Lithium ion battery electrolyte and lithium ion battery 湖州耀宁固态电池研究院有限公司 2023-12-22 CN claimed
US-20200385685-A1 ROBUST DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS INTO ENDOTHELIAL CELLS USING TRANSCRIPTION FACTOR ETV2 CHILDREN'S MEDICAL CENTER CORPORATION 2020-12-10 US claimed
CN-105153126-A Preparation method of bisindolyl maleimide compounds NAT UNIV DONG HWA 2015-12-16 CN claimed
EP-2928466-A1 USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING LEUKEMIA Centogene AG (DE) 2015-10-14 EP claimed
CN-103998444-A Adhesive agent CANCER THERAPEUTICS CRC PTY LTD 2014-08-20 CN claimed
WO-2014090398-A1 USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING LEUKEMIA CENTOGENE AG (DE) 2014-06-19 WO claimed
CN-101671329-B Indolylmaleimide compound substituted with 3-amino alcohol, preparation method and application thereof UNIV DONGHUA 2012-11-07 CN claimed
EP-2305274-A1 Use of WNT stimulators for treating demyelinating diseases Centre National de la Recherche Scientifique (CNRS) (FR) 2011-04-06 EP claimed
CN-101671329-A Indolylmaleimide compound substituted with 3-amino alcohol, preparation method and application thereof UNIV DONGHUA 2010-03-17 CN claimed
US-20090306045-A1 Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-12-10 US claimed
WO-2003104482-A1 SIGNALS AND MOLECULAR SPECIES INVOLVED IN SENESCENCE METABOLIC ENGINEERING LABORATORIES CO., LTD. (KR) 2003-12-18 WO claimed
US-20030143185-A1 Polymer conjugates of protein kinase C inhibitors SHEARWATER CORPORATION 2003-07-31 US claimed
WO-2003037384-A2 POLYMER CONJUGATES OF PROTEIN KINASE C INHIBITORS NEKTAR THERAPEUTICS AL, CORPORATION (US) 2003-05-08 WO claimed
EP-1224932-A1 DRUGS INHIBITING CELL DEATH SAGAMI CHEMICAL RESEARCH CENTER (JP) 2002-07-24 EP claimed
EP-0888339-A4 SYNTHESIS OF INDOLYLMALEIMIDES LILLY CO ELI (US) 2001-02-28 EP claimed
US-5919946-A REACTING AN ACTIVATED MALEIMIDE WITH AN ORGANOMETALLIC-3-INDOLE IN PRESENCE OF A PALLADIUM TRANSITION METAL CATALYST ELI LILLY AND COMPANY (US) 1999-07-06 US claimed
US-5859261-A PROTEIN KINASE INHIBITORS ELI LILLY AND COMPANY (US) 1999-01-12 US claimed
EP-0888339-A1 SYNTHESIS OF INDOLYLMALEIMIDES ELI LILLY AND COMPANY (US) 1999-01-07 EP claimed
WO-1997034890-A1 SYNTHESIS OF INDOLYLMALEIMIDES ELI LILLY AND COMPANY (US) 1997-09-25 WO claimed
EP-0397060-A2 Maleinimide derivatives and their use as medicines GÖDECKE AKTIENGESELLSCHAFT (DE) 1990-11-14 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030143185-A1 Polymer conjugates of protein kinase C inhibitors PRKCH, PRKCI, PRKCA TLR9 1894/4885MGLL 1714/4885DNMT1 1697/4885
US-20090306045-A1 Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease GSK3B, GSK3A, GSKIP TLR9 68/4885MGLL 2289/4885DNMT1 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.